- Home
- Applications
- europe
- cancer risk
Show results for
Refine by
Cancer Risk Product Applications In Europe
3 applications found
Tumor markers found in blood, urine and body tissues can be used in diagnosing and treating cancer. Each tumor marker is indicative of a particular disease and thus can be used for the screening, monitoring and diagnosis of specific tumor types. In addition to being used in prognosis, these molecular markers help to predict the response, resistance and toxicity to therapy. For example, BCR-ABL gene sequence detection is used to diagnose chronic myelogenous leukemia and acute lymphatic ...
ByAurora Biomed Inc. based in Vancouver, BRITISH COLUMBIA (CANADA)
IBD is also strongly associated with colorectal cancer development risk. ...
ByDiagNodus Ltd. based in Cambridge, UNITED KINGDOM
Bladder cancer is the seventh most common cancer diagnosis in worldwide, with 500 000 new cases and 200 000 deaths in 2018 (Globocan 2018). More than 2.7 million people have a history of bladder cancer worldwide. At the initial diagnosis of bladder cancer, more than 80% of cases are diagnosed as non-muscle-invasive bladder cancer (NMIBC). Due to the very high recurrence rate (>80%), NMIBC patients require lifelong surveillance with periodic follow-up cystoscopy (an unpleasant invasive exam) and urine cytology ...
ByOncoDiag based in Miserey, FRANCE